Abstract
There are limited data on nonalcoholic fatty liver disease (NAFLD) from India. The clinicopathological profile of Indian patients with NAFLD may be different from that of Western patients. One hundred NAFLD patients with increased liver enzymes were prospectively evaluated for clinical presentation, associated diseases, overweight/obesity, central obesity (n=54), presence of diabetes mellitus, lipid abnormalities, insulin resistance (n=39), metabolic syndrome (n=54), serum iron, serum ferritin, and transferrin saturation (n=60), and HFE gene mutations (n=30). Risk factors for the grade and stage of the disease on histology were studied in 38 biopsy-proven patients. Patients were treated with lifestyle modifications and ursodeoxycholic acid (UDCA). Seventeen nonresponder patients were treated with metformin. The majority of patients were males (n=70). Twenty percent of patients were overweight, 68% had obesity, and 78% had central obesity. Abnormal cholesterol, HDL, and triglycerides were present in 36%, 66%, and 53% of patients, respectively. Twelve percent of patients had diabetes mellitus and 16% patients had various associated diseases. All 22 (100%) patients studied by ITT and all but 1 (98%) studied by HOMA-IR were found to have reduced insulin sensitivity and 50% were found to have metabolic syndrome by the modified ATP III criteria. Two (3%) patients were found to have high serum iron, 4 (7%) patients had high ferritin, 5 (8%) patients had increased transferrin saturation, and 4 (13%) patients were found to be heterozygotes for H63D HFE gene mutation. Twenty patients of 38 (53%) had histological evidence of NASH (class 3=6, class 4=14). The other 18 (47%) qualified for class I (n=1) or class II (n=17) NAFLD. Four (10.5%) patients had bridging fibrosis and none had evidence of cirrhosis liver. Seventy-four (74%) patients achieved a biochemical response to lifestyle modification and UDCA. All 17 patients treated with metformin had a reduction in ALT level and 10 (59%) of them had normalization of their enzymes. We conclude that the clinicopathological profile of NAFLD in Indian patients is different from that in the West.
Similar content being viewed by others
References
Falck-Ytter Y, Younossi ZM, Marchesini G, Mc Cullough AJ (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17–26
Ludwig J, Viggiano T, McGill D, Ott B (1980) Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 55:434–438
Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U (2002) Cryptogenic cirrhosis: Clinicopathologic findings at and after liver transplantation. Hum Pathol 33:1098–1104
Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, Takasaki K, Ludwig J (2002) Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154–160
Duseja A, Murlidharan R, Bhansali A, Sharma S, Das A, Das R, Chawla Y (2004) Assessment of Insulin resistance and effect of metformin in nonalcoholic steatohepatitis — a preliminary report. Indian J Gastroenterol 23:12–15
Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y (2004) Prevalence of obesity, diabetes mellitus and hyperlipidemia in patients with cryptogenic liver cirrhosis. Trop Gastroenterol 25:15–17
Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y (2005) Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenteorol 11:393–395
Duseja A, Chawla Y (2005) Nonalcoholic fatty liver disease in India — How much? How soon? Trop Gastroenterol 26:1–3
Dhiman RK, Duseja A, Chawla Y (2005) Asians need different criteria for defining overweight and obesity. Arch Intern Med 165:1069–1070
Amarapurkar DN, Patel ND (2004) Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferases values. Trop Gastroenterol 25:130–134
Amarapurkar DN, Patel ND (2004) Prevalence of metabolic syndrome in non diabetic and non cirrhotic patients with non alcoholic steatohepatitis. Trop Gastroenterol 25:125–129
Amarapurkar DN, Amarapurkar AD (2000) Nonalcoholic steatohepatitis: Clinicopathological profile. J Assoc Phys India 48:311–313
Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, Meher C, Rao MVK (2004) Prevalence of nonalcoholic fatty liver disease in coastal eastern India: A preliminary ultrasonographic survey. Trop Gastroenterol 25:76–79
Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa (2004) Non alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19:854–858
Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK (2004) Beneficial affects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99:1946–1952
Agarwal SR, Malhotra V, Sakhuja P, Sarin SK (2001) Clinical, biochemical and histological profile of nonalcoholic steatohepatitis. Indian J Gastroenterol 20:183–86
Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 37:1202–1219
Saverymuttu SH, Joseph AEA, Maxwell JD (1986) Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 292:13–15
Steering Committee of the Western Pacific Region of the World Health Organization, International Association for the Study of Obesity, International Study Task Force (2000) The Asia-Pacific perspective; redefining obesity and its treatment. Health Communications, Australia, pp. 8–56
World Health Organisation (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organisation, Geneva, pp. 31–33
Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment panel III). JAMA 285:2486–2497
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Non-alcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 116:1413–1419
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474
Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002) NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373–379
Mohan V (2004) Why are Indians more prone to diabetes? J Assoc Phys India 52:468–474
Ramachandran A, Snehalatha C, Satyavani K, Vijay V (2003) Impaired fasting glucose and impaired glucose tolerance test in urban population in India. Diabet Med 20:220–224
Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, Sosale A, Munichoodappa C, Seshiah V, Singh SK, Jamal A, Sai K, Sadasivrao Y, Murthy SS, Hazra DK, Jain S, Mukherjee S, Bandyopadhay S, Sinha NK, Mishra R, Dora M, Jena B, Patra P, Goenka K (2004) The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: Prevalence of diabetes in India Study (PODIS). Diabetes Res Clin Pract 66:301–307
Misra A, Vikram NK (2004) Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: Evidence and implications. Nutrition 20:482–491
Misra A, Luthra K, Vikram NK (2004) Dyslipidemia in Asian Indians: Determinants and significance. J Assoc Phys India 52:137–142
Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology 39:770–778
Sanyal AJ (2002) AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123:1705–1725
Angulo P (2002) Nonalcoholic fatty liver disease. N Eng J Med 346:1221–1231
Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30:1356–1362
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver, steatopehatitis and the metabolic syndrome. Hepatology 37:917–923
Day C, James O (1998) Steatohepatitis: A tale of two “hits”? [Editorial]. Gastroenterology 114:842–845
Chitturi S, Weltman M, Farrell GC, McDonald D, Kench J, Liddle C, Samarasinghe D, Lin R, Abeygunasekera S, George J (2002) HFE mutations, hepatic iron, and fibrosis: Ethnic specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36:142–149
Talwalkar JA (2002) Motion — all patients with NASH need to have a liver biopsy: Arguments for the motion. Can J Gastroenterol. 16:718–21
Laurin J (2002) Motion — all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol 16:722–726
Drenick E, Simmons F, Murphy J (1970) Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 282:829–834
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB (1996) Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic induced steatohepatitis: A pilot study. Hepatology 23:1464–1467
Marchesini G, Brizi M, Bianchi G, Tomasserti S, Zoli M, Melchionda N (2001) Metformin in nonalcoholic steatohepatitis. Lancet 358:893–894
Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, Troglitazone in nonalcoholic steatohepatitis. Am J Gastroenterol 96:519–525
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38:1008–1017
Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188–196
Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM (2000) Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 6:998–1003
Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286–1292
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Duseja, A., Das, A., Das, R. et al. The Clinicopathological Profile of Indian Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Different from That in the West. Dig Dis Sci 52, 2368–2374 (2007). https://doi.org/10.1007/s10620-006-9136-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9136-y